The German guidelines for the treatment of anxiety disorders

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 5, 2015, Pages 363-373

  Bandelow, Borwin ^a   Lichte, Thomas ^b   Rudolf, Sebastian ^c   Wiltink, Jörg ^d   Beutel, Manfred E ^d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c Helios Clinic for Psychiatry and Psychosomatic Medicine   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anxiety disorders; Drug treatment; Generalized anxiety disorder; Panic disorder; Psychotherapy; Social phobia; Treatment

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; DULOXETINE; LORAZEPAM; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; BREAST FEEDING; COGNITIVE THERAPY; CONSENSUS; COUNSELING; EVIDENCE BASED MEDICINE; EXERCISE; GERMANY; GROUP THERAPY; HEALTH INSURANCE; HUMAN; ICD-10; INTERPERSONAL THERAPY; LEISURE; PANIC; PHOBIA; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REMISSION; REVIEW; TREATMENT INDICATION; ANXIETY DISORDERS; PROCEDURES; STANDARDS;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; GERMANY; GUIDELINES AS TOPIC; HUMANS;

EID: 84930754652     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-014-0563-z     Document Type: Review

References (35)

1. APA (2009) Practice guideline for the treatment of patients with panic disorder. Work group on panic disorder. American psychiatric association, 2nd edn. American Psychiatric Press, Arlington
2. ÄZQ/AWMF (2008) Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI) 468–519
3. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R (2013) Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat 9:883–892
4. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O’Neill C, Scott J, van der Wee N, Wittchen HU (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the british association for psychopharmacology. J psychopharmacol 28:403–439
5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the british association for psychopharmacology. J psychopharmacol 19:567–596
6. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77–84
7. Bandelow B, Wiltink J, Alpers GW, Benecke C, Deckert J, Eckhardt-Henn A, Ehrig C, Engel E, Falkai P, Geiser F, Gerlach AL, Harfst T, Hau S, Joraschky P, Kellner M, Köllner V, Kopp I, Langs G, Lichte T, Liebeck H, Matzat J, Reitt M, Rüddel HP, Rudolf S, Schick G, Schweiger U, Simon R, Springer A, Staats H, Ströhle A, Ströhm W, Waldherr B, Watzke B, Wedekind D, Zottl C, Zwanzger P, M.E. B (2014) S3-Leitlinie zur Behandlung von Angststörungen
8. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lepine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008) World federation of societies of biological psychiatry (WSFBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312
9. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E (1998) Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155:603–609
10. Canadian Psychiatric Association (2006) Canadian psychiatric association clinical practice guidelines, management of anxiety disorders. Can J Psychiatry 58:1S–92S
11. DIMDI (2013) Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision, German Modification (icd-10-gm)
12. Dresler T, Guhn A, Tupak SV, Ehlis AC, Herrmann MJ, Fallgatter AJ, Deckert J, Domschke K (2013) Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm 120:3–29
13. Eccles M, Mason J (2001) How to develop cost-conscious guidelines. Health Technol Assess (Winchester, England) 5:1–69
14. GIN (2012) Guidelines international network. http://www.g-i-n.net/. Accessed 14 Nov 2014
15. Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S, Fydrich T, Fehm L, Hamm AO, Richter J, Alpers GW, Gerlach AL, Strohle A, Kircher T, Deckert J, Zwanzger P, Hofler M, Arolt V (2011) Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in cbt. J Consult Clin Psychol 79:406–420
16. Heinrichs N, Alpers GW, Gerlach AL (2009) Evidenzbasierte Leitlinien zur Psychotherapie der Panikstörung mit und ohne Agoraphobie und der agoraphobie ohne Panikstörung im Auftrag der Fachgruppe Klinische Psychologie und Psychotherapie in der deutschen Gesellschaft für Psychologie (dgp). Hogrefe, Göttingen
17. Heinrichs N, Stangier U, Gerlach A, Willutzki U, Fydrich T (2010) Evidenzbasierte Leitlinie zur Psychotherapie der sozialen Angststörung. Hogrefe, Göttingen
18. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70
19. Jacobi F, Hofler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen HU (2014) mental disorders in the general population: study on the health of adults in germany and the additional module mental health (degs1-mh). Nervenarzt 85:77–87
20. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, Lieb R (2004) Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German health interview and examination survey (ghs). Psychol Med 34:597–611
21. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM (2005) Prevalence and treatment of mental disorders, 1990–2003. N Engl J Med 352:2515–2523
22. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 51:8–19
23. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21:169–184
24. Moher D, Altman DG, Liberati A, Tetzlaff J (2011) Prisma statement. Epidemiology 22:128
25. NICE (2011) National institute for health and clinical excellence (nice). Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. The British Psychological Society and The Royal College of Psychiatrists. www.nice.org.uk
26. NICE (2013) National institute for health and clinical excellence (nice). Social anxiety disorder: Recognition, assessment and treatment (full guideline). The British Psychological Society and The Royal College of Psychiatrists
27. Oyebode F, Rastogi A, Berrisford G, Coccia F (2012) Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 135:71–77
28. Priebe S, Wright D (2006) The provision of psychotherapy: an international comparison. J Public Ment Health 5:12–22
29. SIGN (2012) Scottish intercollegiate guidelines network www.Sign.Ac.Uk
30. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, Colucci R, Corona T, Blandizzi C, Del Tacca M (2009) Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 31(Pt 1):1426–1453
31. Udechuku A, Nguyen T, Hill R, Szego K (2010) Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 44:978–996
32. Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B (2010) A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry 11:904–913
33. WHO (1991) World Health Organisation. Tenth revision of the international classification of diseases, chapter v (f): Mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva
34. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–679
35. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(Suppl 8):24–34